NDAINHALATIONGAS
Approved
Jun 2022
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
7
Data completeness
3/8 — Basic
Nitrogen, NF (nitrogen) by Advanced Solutions Life Sciences. Approved for critical illness, gastrointestinal neoplasms, postoperative complications and 8 more indications. First approved in 2022.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Nitrogen, NF is an inhaled gas product approved in June 2022 by Advanced Solutions Life Sciences for a broad range of indications spanning critical illness, gastrointestinal neoplasms, postoperative complications, and dermatological conditions. The product's mechanism of action and pharmacologic class remain unspecified in available data, limiting clarity on its clinical differentiation. It is currently in peak commercial lifecycle.
Peak
Product is at peak commercial stage with moderate competitive pressure (30/100), suggesting active brand management and field team deployment but no immediate growth acceleration.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Worked on Nitrogen, NF at Advanced Solutions Life Sciences? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.